Retirement Systems of Alabama Sells 374 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Retirement Systems of Alabama decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,793 shares of the biopharmaceutical company’s stock after selling 374 shares during the period. Retirement Systems of Alabama’s holdings in Regeneron Pharmaceuticals were worth $16,236,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in REGN. Paragon Capital Management Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $1,257,000. 1858 Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $224,000. Avitas Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 12.7% in the 4th quarter. Avitas Wealth Management LLC now owns 372 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 42 shares in the last quarter. Redwood Wealth Management Group LLC increased its position in shares of Regeneron Pharmaceuticals by 4.2% during the 4th quarter. Redwood Wealth Management Group LLC now owns 497 shares of the biopharmaceutical company’s stock valued at $354,000 after purchasing an additional 20 shares during the last quarter. Finally, Ninety One UK Ltd raised its holdings in shares of Regeneron Pharmaceuticals by 14.4% during the 4th quarter. Ninety One UK Ltd now owns 78,005 shares of the biopharmaceutical company’s stock valued at $55,565,000 after buying an additional 9,820 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.7 %

NASDAQ:REGN opened at $722.07 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm’s 50-day moving average price is $717.27 and its 200-day moving average price is $914.93. The company has a market capitalization of $79.35 billion, a PE ratio of 17.87, a P/E/G ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Thursday, February 20th.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on REGN. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $762.00 to $834.00 in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.